vs
Side-by-side financial comparison of Falcon's Beyond Global, Inc. (FBYD) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $6.6M, roughly 1.4× Falcon's Beyond Global, Inc.). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -4.5%, a 5.1% gap on every dollar of revenue. On growth, Falcon's Beyond Global, Inc. posted the faster year-over-year revenue change (383.5% vs -3.0%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-4.3M). Over the past eight quarters, Falcon's Beyond Global, Inc.'s revenue compounded faster (108.4% CAGR vs 17.3%).
500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
FBYD vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.6M | $9.3M |
| Net Profit | $-296.0K | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | -30.9% | 5.3% |
| Net Margin | -4.5% | 0.6% |
| Revenue YoY | 383.5% | -3.0% |
| Net Profit YoY | 97.5% | 101.3% |
| EPS (diluted) | $-0.01 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.6M | $9.3M | ||
| Q3 25 | $4.1M | $6.9M | ||
| Q2 25 | $2.5M | $7.7M | ||
| Q1 25 | $1.7M | $6.8M | ||
| Q4 24 | $1.4M | $9.6M | ||
| Q3 24 | $2.1M | $8.8M | ||
| Q2 24 | $1.8M | $8.4M | ||
| Q1 24 | $1.5M | $6.8M |
| Q4 25 | $-296.0K | $58.0K | ||
| Q3 25 | $-10.4M | $-1.6M | ||
| Q2 25 | $25.1M | $-2.6M | ||
| Q1 25 | $-8.1M | $-2.1M | ||
| Q4 24 | $-11.9M | $-4.6M | ||
| Q3 24 | $39.3M | $-2.1M | ||
| Q2 24 | $8.0M | $-91.0K | ||
| Q1 24 | $114.0M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | -30.9% | 5.3% | ||
| Q3 25 | -90.9% | -16.9% | ||
| Q2 25 | -53.0% | -30.1% | ||
| Q1 25 | -371.1% | -25.0% | ||
| Q4 24 | -335.6% | -44.7% | ||
| Q3 24 | -118.9% | -18.2% | ||
| Q2 24 | -195.9% | -5.7% | ||
| Q1 24 | -350.5% | -42.7% |
| Q4 25 | -4.5% | 0.6% | ||
| Q3 25 | -256.8% | -23.4% | ||
| Q2 25 | 985.2% | -33.6% | ||
| Q1 25 | -473.8% | -31.2% | ||
| Q4 24 | -871.7% | -47.6% | ||
| Q3 24 | 1899.5% | -23.6% | ||
| Q2 24 | 446.5% | -1.1% | ||
| Q1 24 | 7521.4% | -49.8% |
| Q4 25 | $-0.01 | $0.14 | ||
| Q3 25 | $-0.13 | $-0.36 | ||
| Q2 25 | $0.30 | $-0.62 | ||
| Q1 25 | $-0.13 | $-0.51 | ||
| Q4 24 | $-0.25 | $-2.01 | ||
| Q3 24 | $0.39 | $-0.51 | ||
| Q2 24 | $0.00 | $-0.03 | ||
| Q1 24 | $1.27 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9M | $7.9M |
| Total DebtLower is stronger | $15.6M | $15.3M |
| Stockholders' EquityBook value | $11.9M | $2.9M |
| Total Assets | $66.7M | $30.5M |
| Debt / EquityLower = less leverage | 1.31× | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9M | $7.9M | ||
| Q3 25 | $4.3M | $7.1M | ||
| Q2 25 | $26.1M | $6.0M | ||
| Q1 25 | $1.1M | $6.5M | ||
| Q4 24 | $825.0K | $7.3M | ||
| Q3 24 | $828.0K | $7.1M | ||
| Q2 24 | $1.7M | $5.5M | ||
| Q1 24 | $1.1M | $5.2M |
| Q4 25 | $15.6M | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | $41.2M | $15.0M | ||
| Q3 24 | $10.3M | $15.0M | ||
| Q2 24 | $15.7M | $15.0M | ||
| Q1 24 | $15.1M | $15.0M |
| Q4 25 | $11.9M | $2.9M | ||
| Q3 25 | $9.2M | $1.3M | ||
| Q2 25 | $414.0K | $532.0K | ||
| Q1 25 | $-11.6M | $3.0M | ||
| Q4 24 | $-9.0M | $5.0M | ||
| Q3 24 | $-1.4M | $9.4M | ||
| Q2 24 | $-44.7M | $9.5M | ||
| Q1 24 | $-61.7M | $9.4M |
| Q4 25 | $66.7M | $30.5M | ||
| Q3 25 | $66.8M | $30.7M | ||
| Q2 25 | $89.2M | $29.5M | ||
| Q1 25 | $56.7M | $33.0M | ||
| Q4 24 | $61.2M | $34.9M | ||
| Q3 24 | $66.5M | $39.4M | ||
| Q2 24 | $65.9M | $38.8M | ||
| Q1 24 | $67.8M | $39.2M |
| Q4 25 | 1.31× | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.3M | $-239.0K |
| Free Cash FlowOCF − Capex | $-4.3M | $-551.0K |
| FCF MarginFCF / Revenue | -66.0% | -5.9% |
| Capex IntensityCapex / Revenue | 0.3% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.3M | $-239.0K | ||
| Q3 25 | $-13.3M | $-64.0K | ||
| Q2 25 | $-7.9M | $-1.9M | ||
| Q1 25 | $945.0K | $-550.0K | ||
| Q4 24 | $-3.8M | $703.0K | ||
| Q3 24 | $-2.4M | $-302.0K | ||
| Q2 24 | $-2.6M | $591.0K | ||
| Q1 24 | $-3.8M | $-804.0K |
| Q4 25 | $-4.3M | $-551.0K | ||
| Q3 25 | $-13.4M | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | $853.0K | $-749.0K | ||
| Q4 24 | $-3.8M | $199.0K | ||
| Q3 24 | $-2.4M | $-364.0K | ||
| Q2 24 | $-2.6M | $246.0K | ||
| Q1 24 | $-3.8M | $-1.5M |
| Q4 25 | -66.0% | -5.9% | ||
| Q3 25 | -329.6% | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | 49.9% | -11.0% | ||
| Q4 24 | -278.7% | 2.1% | ||
| Q3 24 | -114.9% | -4.1% | ||
| Q2 24 | -145.6% | 2.9% | ||
| Q1 24 | -248.8% | -22.6% |
| Q4 25 | 0.3% | 3.4% | ||
| Q3 25 | 1.0% | 14.7% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 5.4% | 2.9% | ||
| Q4 24 | 0.1% | 5.3% | ||
| Q3 24 | 0.2% | 0.7% | ||
| Q2 24 | 0.1% | 4.1% | ||
| Q1 24 | 0.3% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.06× | — | ||
| Q2 24 | -0.33× | — | ||
| Q1 24 | -0.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FBYD
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
